Chronic lymphocytic leukemia (CLL) has consistent 13q chromosomal abnormalities detected by conventional cytogenetics. Using interphase cytogenetics we show deletion of a l-megabase 13q12.3 locus, encompassing the 6RCAZ gene, in 80% of 35 CLL cases studied. Homozygous deletion of 6RCA.2, located within the minimal deletion consensus, was detected in a significant population of cells in 60% of the cases. Deletion of the previously described 13q14 locus (analyzed with R67 and D13S25 probes) was seen in 63% of the cases. Homozygous deletion of R67 was seen in one HRONIC LYMPHOCYTIC leukemia (CLL), the most common leukemia of adults in the western world, is characterized by the clonal expansion of neoplastic CDS' B cells in the blood, bone marrow, lymph nodes, and spleen. Chromosomal abnormalities have been described in about 50% of CLL patients using conventional cytogenetics. ' The most common are trisomy 12 (10% to 18%) and structural aberrations of 13q14 (10% to 28%), including interstitial deletions similar to those previously described in retinoblast~m a . "~ Indeed, several studies of CLL (using Southern blotand/or polymerase chain reaction [PCRI-microsatellitebased assays) have found allelic deletion of the retinoblastoma gene (RBI) in 21% to 30% of patient^.^.^ Notwithstanding this, evidence for the inactivation of RBI in CLL is scarce and mutations in the remaining allele in cases with loss of heterozygosity (LOH) have not been detected.6 The D13S25 marker located at 13q14, 1 megabase (Mb) telomeric to RBI, is more frequently deleted in CLL than RBI (24% to 60% of Homozygous deletion of a genomic region near this marker has suggested that a new tumor supressor gene, called DBM (deleted in B-cell malignancy), might be implicated in CLL.lo."
(23/39) have a centromeric boundary at 13q12.2~4.h~7~'" The recently cloned breast cancer susceptibility gene BRCAZ has been mapped to 13q12.3, about 24 centiMorgans (CM) centromeric to RBI,'*,'' which could lie within some of the cytogenetically defined deletions (13q12-14) in CLL. To better characterize these 13q deletions, we performed fluorescence. in situ hybridization (FISH) on a series of 35 patients with CLL using probes for the 13q12 locus, where BRCA2 is located, and for the 13q 14 locus, were DBM is located.
MATERIALS AND METHODS

Patient and Control Samples
Thirty-five cases of CLL were randomly chosen from two groups of patients previously characterized for allelic loss at the REI locus: 13 patients with RBI deletion and 22 cases without RBI allelic loss. This distribution was representative of the overall series of 320 CLL patients prospectively collected in our Haematology Department.14 The diagnosis of CLL was based on morphologic examination and immunologic rnarker~.'~ Mononuclear cells from peripheral blood (PB) samples of 25 normal probands were used as controls for evaluation of hybridization efficiency of the different unique sequence DNA probes.
Conventional Cytogenetics
Ficoll-Hypaque (Nyegaard, Oslo, Norway) separated mononuclear cells were cultured at 37°C in the presence of tetradecanoyl-phorbolacetate (TPA; 0.05 ,ug/mL) for 3 to 5 days and standard cytogenetic preparations were made, G banded, and karyotyped according to the International System for Cytogenetic Nomenclature. 16 
FISH
Probes. Two genomic ERCAZ probes were used: a PAC clone (234i22) containing most of the BRCA2 gene and a plasmid (~12120) with a ERCAZ fragment of 12 kb extending from intron 9 to intron 11, subcloned from PAC 234i22 (A.A., unpublished observations, November 1995). Probes for the 13q14 region were LSI-RB1, a P1 contig containing the REI gene, and cosD13S25, a cosmid clone containing marker D13S25. Three PAC clones previously mapped to 13q12 were obtained from Richard Wooster (ICR, Sutton, UK):
9@2, 181~10, and 17m7. These PACs were fingerprinted as part of the effort to clone the BRCA2 gene and shown to contain markers, respectively, D13S289, D13S109, and D13S171 (Fig 1) . Cosmid probes used as hybridization efficiency controls were: cosMYCN (chromosome 2p2.5), cos2lqter (chromosome 2lqter). cosG9 and cosF9 (5' end and 3' end of EWS gene, chromosome 22q1.2). These were selected because they are from chromosomal sites rarely deleted in CLL. All 35 cases were tested with probes p12120RIRCA2, LS1-RBI, and cosD13S25. DNA probes (except LSI--1) were labeled with biotin 11-dUTP or digoxigenin 11-dUTP using nick translation according to the manufacturer's protocol (Boehringer Mannheim, Bell Lane, UK). LSI-RB 1 was obtained directly labeled with spectrum orange (Vysis Inc, Downers Grove, IL). Labeled probe (200 to 250 ng per hybridization spot) was mixed with COT1 human DNA (100-fold excess DNA per probe), and 1 pg of hemng sperm DNA. The mixture was ethanol precipitated and resuspended in 5 pL of hybridization solution (50% deionized formamide, 2X SSC, 10% dextran sulfate, pH 7).
Hybridization. Slides for FISH were prepared using cells from directly harvested PB mononuclear cells (except for CLL14 where only lymphocytes from TPA-stimulated short-term cultures were available) incubated with hypotonic solution, fixed with Carnoy's fixative, and stored at -20°C until use. All FISH experiments included two different unique sequence DNA probes in the same slide, one being the internal control for hybridization efficiency. Two types of hybridization efficiency controls were used: a probe from another chromosome to ensure that more than 97% of the cells had two control hybridization spots or a probe in another locus of the q arm of chromosome 13 (LSI-RB1, cosD13S25, or 90p2D13S289). This other 13q probe served three purposes: control of hybridization efficiency, control for random loss of material at chromosome 13q, and mapping the limits of the deletion. Cohybridization was performed as follows: slides were denatured in 65% formamide/2~ SSC for 5 minutes at 70°C and dehydrated in 70%. 90%, and 100% ethanol series. LSI-RBI probe was denatured for 5 minutes at 70°C and placed onto prewarmed slides and the remaining probes were denatured for 10 minutes at 70°C and allowed to preanneal at 37°C for 30 minutes. After overnight hybridization, the slides were washed in 50% formamidel2x SSC for 30 minutes, 2X SSC for 10 minutes, and 4X SSC/Triton X-100 (Pharmacia Biotech, Uppsala, Sweden) for 5 minutes. All washes were performed at 45°C. The 
RESULTS
Conventional Cytogenetics
Evaluable metaphases were obtained in 30 of 35 patients. Thirteen of 30 patients (43%) had clonal chromosomal abnormalities. Interstitial deletions of 13q were detected in 7 patients (23%). Trisomy 12 was seen in 7 patients, 4 of whom also had a 13q deletion.
FISH on Control Samples
Analysis of the control probes (cosmids for chromosomes 2, 21, and 22) in normal PB samples showed an average of 97% of cells with two hybridization signals. Analysis of test probes was only performed on slides with similar hybridization efficiency and only cells with two signals for the control probe were scored. Definition of the cut-off level for allelic deletion was based on published criteria": the mean percentage of cells with one hybridization signal plus 3 standard deviations, determined by scoring interphase cells from 25 normal controls (a total of at least 2,000 cells was scored). We arbitrarily defined that homozygous deletion was present when more than 5% of the cells in CLL samples had no For personal use only. on August 30, 2017. by guest www.bloodjournal.org From hybridization signal for the target probe and two hybridization signals for the control probe.
BRCAZ Is Frequently Deleted in CLL
Deletion of BRCA2 was detected using the BRCAZ plasmid probe (~12120) in 28 of 35 (80%) patients studied ( Figs  2 and 3 ). AI1 28 cases had a percentage of celIs with BRCA2 deletion at least four times the defined cut-off level (Fig 3) . Seven cases had hemizygous deletion of BRCAZ One case (CLL13) had homozygous deletion of BRCA2 (93% of the cells with zero hybridization signals). In the remaining 20 patients (71% of cases with BRCA2 allelic deletion) there were two distinct populations of cells with BRCA2 loss: cells exhibiting a homozygous deletion (representing from 13% to 53% of cells with deletion) and cells with hemizygous deletion (representing 47% to 87% of cells with deletion) (Figs 2 and 4) .
A group of 14 samples was also tested for allelic deletion at the 13q12.3 locus using a PAC clone (234i22) from the contig used to clone BRCA2. This PAC clone, with a 120-to 150-kb insert, was shown to contain most of the BRCA2 gene, including its 3' end (data not shown). Results of hybridization with this PAC probe were concordant with results obtained with plasmid p12120/BRCA2 in 10 cases (Fig 5) . In 3 cases (CLL6, CLL7, and CLL13) a clone of cells with homozygous deletion was only detected using probe p12120/ BRCA2, whereas hemizygous deletion was shown with both probes. In I case (CLLlS) deletion of BRCA2 was shown only when using the BRCAZ plasmid probe. Results in these 4 cases are more likely explained by the fact that the PAC probe contains most of the BRCA2 gene as well as up to 70 kb of 3' flanking sequence and could therefore fail to show small deletions.
To confirm that the results were not caused by inefficient hybridization, the percentage of cells with either one or zero BRCA2 signals and two chromosome 21 signals in cohybridization slides was calculated; the value obtained was the same as the percentage of cells with BRCAZ deletion counted by single-color evaluation. In addition, the percentage of cells with BRCA2 deletion was constant from hybridization to hybridization (data not shown).
Most cases with BRCA2 deletion were tested with other PAC probes at 13q12: 90p2/D13S289, 181clO/D13S109, and 17m7/D13S171 (Fig 5) . Deletion with these probes was seen, respectively, in 15% (3/20), 30% (6/20), and 9% ( l / 11) of the cases tested.
Deletion at 13q14
Deletion of D13S25 (cosD13S25) was detected in 22/35 cases (63%) and allelic loss (homozygous in a single case) of RBI was detected in 13/35 (37%) cases (Figs 3 and 5) . In 7 of the 22 cases (32%) with D13S2.5 allelic loss, there was a significant percentage of cells with homozygous deletion (average, 20%; range, 7.5% to 52%). BRCA2 allelic loss was seen in all 22 cases with D13S25 allelic deletion. In contrast D13S25 allelic loss was seen in 79% (22/28) of cases with BRCA2 allelic deletion. All cases with RBI loss also had BRCAZ loss, whereas only 46% of cases with BRCAZ allelic loss had a simultaneous deletion of RBI.
Percentage of Cells With Allelic Deletion
The percentage of cells with BRCA2 allelic deletion (0 or 1 hybridization signals per cell) was determined by scoring 400 to 600 cells and averaged 63% (range, 25% to 96%) (Fig  3) . In several cases this underestimates the value because in the sample analyzed the proportion of clonal B cells (defined by the restricted expression of cell-surface Ig light-chain and/or by surface expression of both CD5 and CD19) was less than 95% (Fig 4) . In 21 cases (60%) the percentage of cells with BRCA2 deletion was higher than 50%. The mean percentage of cells with allelic deletion of RBI and D13S25 was respectively 57% (range, 23% to 94%) and 52% (range, 20% to 88%) (Fig 3) . In 17 of 22 cases with simultaneous allelic loss at 13q12 (BRCAZ) and 13q14 (RBI and/or D13S25) the percentage of cells with allelic deletion (hemizygous and homozygous) of BRCA2 was at least as high as at the 13q14 locus (Fig 3) .
Definition of n Minimal Deletion Consensus a f 13q12
In 22 cases there was deletion of both 13q12 and 13q14 (RBi and D13S25 or D13S25 alone) and it was important to determine if this was the result of loss of a large fragment of chromosome 13q encompassing both loci. Retention of both alleles of RBI in 9 of these cases established that this gene lies telomeric to the 13q12 deletion locus (Fig 5) . Of the remaining 13 cases, 11 were tested with the PAC 17m7/ D1 3 s 17 1, which maps less than 500 kb telomeric to BRCAZ, and 10 showed retention of both alleles (Fig 5) . These data clearly established that the deletions at each of the two loci are not contiguous and therefore represent distinct genetic events.
Two PAC probes mapped centromeric to BRCA2 were used to define the minimal deletion consensus at 13q12 (Figs   1 and 5) . We first tested PAC 9@2/D13S289, which maps 3 to 4 CM centromeric to BRCA2: two copies were retained in 17 of 20 cases studied. In one case (CLLl3) with hemizygous deletion of 90p2/D13S289, BRCA2 homozygous deletion was present in 93% of the cells. These data clearly established that D13S289 is located proximal to the centromeric boundary of the interstitial 13q12 deletions in 90% of the cases. PAC 181clO/D13S109, which lies about 1 Mb centromeric to BRCAZ, was disomic in 11 of 16 cases tested. In the 5 cases with hemizygous loss there were cells with homozygous deletion of BRCA2. Data from this PAC together with PAC 17m7/D13S171 defined a minimal hemizygous deletion consensus of about 1 Mb.
Detection of Heterogeneous Clones
Dual hybridizations with BRCA2 and 13q14 probes (RBI or D13S25) were performed in most cases, which made possible scoring allelic deletion at the two 13q loci (BRCA2 and DBM) in the same cell. Cases with simultaneous BRCA2, RBI, and D13S25 deletion (except for CLL13), were tested by dual hybridization with BRCA2 and RBI probes. The dominant clone in 9 cases, representing an average of 49% of the cells (range, 25% to 79%), was formed by cells with deletion of both BRCAZ and UBI. Two minor clones coexisted in these cases: 1 with BRCA2 deletion and no loss of RBI (mean, 15% of the cells; range, 2.5% to 25%) and 1 with RBI deletion and disomy at BRCAZ (mean, 18% of the cells; range, 9% to 29%). Three patients (CLL2, CLL7, CLL12) had a dominant clone of cells with disomy of RBI and deletion of BRCAZ (mean, 38% of the cells; range, 27% to 53%). A second clone (mean, 22% of the cells; range, 20% to 24%) had deletion of both RBI and BRCAZ. A minor clone had retention of both BRCAZ alleles and RB 1 deletion (mean, 4% of the cells). Allelic loss of both BRCA2 and D13S25 was seen in 9 of 22 cases without RBI deletion. In 4 of these cases cohybridization with BRCAZ and D13S25 probes was done. In 2 patients (CLL14, CLL3 l ) 2 independent clones existed: l clone with D13S25 allelic loss and disomy of BRCA2 and another clone with the reverse (BRCAZ allelic loss and disomy at D13S25). In the other 2 cases (CLL28 and CLL33) studied 3 clones were identified: 1 with BRCA2 allelic loss, 1 with D13S25 allelic loss, and 1 with allelic loss of both loci.
DISCUSSION
Human cancers result from the evolution of cell populations that acquire clonal advantage over surrounding cells by the successive accumulation of alterations in genes of two distinct classes: proto-oncogenes and tumor suppressor genes.'* Although the molecular pathogenesis of CLL is poorly defined, both amplification of oncogenes and deletion or mutation of tumor suppressor genes have been described."
Alterations in tumor suppressor genes are considered recessive and result in the functional inactivation of both alleles." This is usually accomplished by intragenic mutation in one allele and deletion of the chromosome segment containing the other allele. It is for this reason that chromosomal regions subject to frequent LOH are considered to be potential sites of tumor suppressor genes." An alternative way to inactivate a gene is the deletion of both alleles (homozygous deletion) with the same end result of its functional inactivation. This is the main genetic mechanism in the case of the recently cloned tumor suppressor genes MTSl/pl6/CDKN2 and DPC4.22.2 ' We present data from interphase cytogenetic analysis of CLL, a common human B-cell neoplasm, that provides strong evidence for the existence of a new tumor suppressor locus located centromeric to RBI and encompassing the recently cloned breast cancer susceptibility gene BRCAZ. mapped to 13q12.3.12.13.24 This new putative tumor suppressor locus is more commonly deleted than the DBM locus at 13q14. Frequent allelic deletion of the DBM locus, distal to RBI and near the marker D13S25, was also confirmed. Monoallelic deletion of RB 1 was present in 12 of 34 patients (35%), and allelic deletion of D13S25 in 22 of 35 cases (63%). One patient had homozygous deletion of RBI. These frequencies are comparable to those reported in previous studies of allelic loss in CLL using
Having shown the frequent deletion of the 13q12.3 locus using a BRCAZ probe it was important to determine the size of the deletion. A minimal deletion consensus for monoallelic loss of about 1 Mb, flanked by markers D13S109 and D13S171, was defined. This is a remarkable finding because most hemizygous deletions at tumor suppressor loci are large, frequently extending to a whole chromosomal arm. LOH at the BRCAZ locus has been reported in sporadic breast and pancreatic carcinomas but in both tumors the deletions extend over at least 25 Mb and almost always encompass the RBI IOCUS.~'.*~ Homozygous deletion of the BRCAZ gene, located within the minimal deletion consensus, was seen in a population of clonal cells in 60% of the 35 cases studied. Results of hybridization in 4 cases (CLL6, CLL7, CLL13, and CLL14) are suggestive of an intragenic deletion, similar to previously described deletions of the tumor suppressors RBI, MTSI, and DPC4.23 In these cases a clone of cells with no hybridization signal was only detected when using the probe containing a fragment of BRCAZ, suggesting a small deletion with a breakpoint within the gene. In any case, it appears that the homozygous deletions of BRCAZ in CLL represent a clonal evolution event occurring after clonal expansion and loss of a single allele because, with the exception of 2 patients (CLL13 and CLL30). most cells had only hemizygous deletion. The coexistence of clones with hemizygous and clones with homozygous deletion of a tumor suppressor gene or locus in a neoplasm is not ~nprecedented*~.*~ (C.M.P., unpublished observations, May 1996).
Southern blot-and PCR-based assessments of allelic loss rely on the purity of the tumor cell population and on the event occumng in most of the cells. In other words, these methods rely on scoring cell population and not individual cell changes. This can be a relative advantage because only genetic changes in the dominant clone are scored, although minor clones are overlooked. Clonal evolution, resulting from the progressive accumulation of genetic events, is the generally accepted model of tumor progression." The model would predict tumor heterogeneity, as we describe here. Molecularly characterized clonal heterogeneity was previously noted in colon and pancreatic cancer^.".^' Tumor heterogeneity probably reflects the coexistence of both parental and competing subclones within the neoplasm, despite the presence of the dominant subclone that accounts for the bulk of the neoplasm.-" FISH is particularly well suited to study clonal variation because individual cells are scored and accurate allele count does not require absolute clonal dominance. By studying allelic deletion at just two loci (1 3q12 and 13q14) we were able to show that minor variant clones coexisted with a dominant clone. Cells with BRCAZ allelic deletion represented only a fraction of clonal malignant cells in the sample in several cases. This would suggest that in these cases the allelic loss at the For personal use only. on August 30, 2017. by guest www.bloodjournal.org From BRCAZ locus is secondary to the clonal expansion of CD5+ B cells. The nature of the earlier event associated with this clonal expansion in CLL is still unknown.
In summary, allelic deletions at the 13q12.3 locus around BRCAZ represent the most common genetic event so far described in CLL. Somatic inactivation of BRCAZ, caused by homozygous deletion of the gene in a fraction of clonal cells, was seen in most of the CLL cases studied but appeared to be a secondary event. Mutational analysis of BRCAZ in CLL (and other tumors with 13q12.3 deletion) may help define if it is the true target of these allelic loss events. In addition, study of the expression of BRCAZ in both normal and malignant B cells will be necessary to determine if loss of expression of the gene is responsible for the tumorigenic phenotype. 
